Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics (NQ: CRDL )

1.790 -0.050 (-2.72%)
Streaming Delayed Price Updated: 12:57 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,346
Open 1.810
Bid (Size) 1.790 (12)
Ask (Size) 1.800 (10)
Prev. Close 1.840
Today's Range 1.790 - 1.840
52wk Range 0.5500 - 2.170
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
This is a Designated News Release.Toronto, Ontario--(Newsfile Corp. - February 21, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)... 
Via Newsfile

Performance

YTD
+103.41%
+103.41%
1 Month
-1.65%
-1.65%
3 Month
+61.26%
+61.26%
6 Month
+123.67%
+123.67%
1 Year
+203.39%
+203.39%

More News

Read More
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Via Newsfile
Exposures Product Safety
Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Via Newsfile
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via Get News
Topics Death
Exposures Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via News Direct
Topics Death
Exposures Death
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
Via TheNewswire.com
Topics Death
Exposures Death
Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations
Via Benzinga
CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects
Via Benzinga
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
Via Newsfile
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
Via Newsfile
Sidoti's Micro-Cap Virtual May Conference
Via ACCESSWIRE
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
Via Newsfile
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
Air Pollution is a Global Heart and Lung Health Concern
Via FinancialNewsMedia
Topics Climate Change Emissions Energy
Exposures Climate Fossil Fuels
The Healthcare Companies Fighting the World’s Biggest Killers
Via FinancialNewsMedia
Tackling Recurring Health Conditions Offers Hope to Patients
Via FinancialNewsMedia
As Health Problems Mount Patients Welcome New Treatments
Via FinancialNewsMedia
Breakthroughs In Treating Killer Diseases Could Lengthen Life
Via FinancialNewsMedia
Topics Death
Exposures Death
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.